NASDAQ:DBTX

Decibel Therapeutics Stock Forecast, Price & News

$9.89
-0.86 (-8.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.83
Now: $9.89
$10.86
50-Day Range
$10.41
MA: $13.65
$18.78
52-Week Range
$10.20
Now: $9.89
$24.39
Volume68,604 shs
Average Volume178,290 shs
Market Capitalization$246.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin, or OTOF, gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy, or BVP, by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was founded in 2013 and is based in Boston, Massachusetts.
Decibel Therapeutics logo

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DBTX
CUSIPN/A
CIKN/A
Phone617 370 8701
Employees40
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$246.28 million
Next Earnings Date7/5/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

2.23 out of 5 stars

Medical Sector

24th out of 2,025 stocks

Biotechnology Industry

2nd out of 148 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$9.89
-0.86 (-8.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for DBTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Decibel Therapeutics (NASDAQ:DBTX) Frequently Asked Questions

Is Decibel Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Decibel Therapeutics stock.
View analyst ratings for Decibel Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Decibel Therapeutics?

Wall Street analysts have given Decibel Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Decibel Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Decibel Therapeutics' next earnings date?

Decibel Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, July 5th 2021.
View our earnings forecast for Decibel Therapeutics
.

What price target have analysts set for DBTX?

5 analysts have issued 1-year price objectives for Decibel Therapeutics' shares. Their forecasts range from $26.00 to $30.00. On average, they expect Decibel Therapeutics' share price to reach $28.80 in the next twelve months. This suggests a possible upside of 191.2% from the stock's current price.
View analysts' price targets for Decibel Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Decibel Therapeutics' key executives?

Decibel Therapeutics' management team includes the following people:
  • Dr. Laurence E. Reid, Pres, CEO & Director (Age 57, Pay $789.5k)
  • Mr. John J. Lee, Exec. VP of Pharmaceutical Devel. & Interim CSO (Age 53, Pay $808.62k)
  • Ms. Anna Trask, Chief People, Community & Culture Officer (Age 63, Pay $485.44k)
  • Mr. M. Charles Liberman, Co-Founder & Member of Scientific Advisory Board
  • Dr. Gabriel Corfas, Co-Founder & Member of Scientific Advisory Board
  • Dr. Ulrich Müller, Co-Founder & Member of Scientific Advisory Board
  • Dr. Albert S. B. Edge, Co-Founder & Member of Scientific Advisory Board (Age 66)
  • Dr. Elisabeth Leiderman M.B.A., M.D., CFO & Head of Corp. Devel. (Age 44)
  • Mr. John J. Keilty, Chief Data Sciences Officer
  • Mr. Joe Burns Ph.D., Head of Biology & VP

Who are some of Decibel Therapeutics' key competitors?

When did Decibel Therapeutics IPO?

(DBTX) raised $100 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays served as the underwriters for the IPO.

What is Decibel Therapeutics' stock symbol?

Decibel Therapeutics trades on the NASDAQ under the ticker symbol "DBTX."

When does the company's lock-up period expire?

Decibel Therapeutics' lock-up period expires on Wednesday, August 11th. Decibel Therapeutics had issued 7,062,000 shares in its IPO on February 12th. The total size of the offering was $127,116,000 based on an initial share price of $18.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Decibel Therapeutics?

Shares of DBTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Decibel Therapeutics' stock price today?

One share of DBTX stock can currently be purchased for approximately $9.89.

How much money does Decibel Therapeutics make?

Decibel Therapeutics has a market capitalization of $246.28 million.

How many employees does Decibel Therapeutics have?

Decibel Therapeutics employs 40 workers across the globe.

What is Decibel Therapeutics' official website?

The official website for Decibel Therapeutics is decibeltx.com.

How can I contact Decibel Therapeutics?

The company can be reached via phone at 617 370 8701.


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.